BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

BioNTech SENASDAQ: BNTX

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 8.1%

Gross margin was 8.1% in Q2 FY2026, down 62.6 pp from a year earlier. On a trailing-twelve-month basis it was 70.8%, down 8.9 pp year over year. Over 3 fiscal years it narrowed by 5.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
8.1%+71.3 pp QoQ
Last fiscal yearDec 2025
77.6%-2.7 pp YoY
LTMJun 2026
70.8%-8.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-62.6 pp——
1 year-2.7 pp——
3 years-5.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
77.6%
Year-over-year change
-2.7pp

Gross Margin vs competitors

How BNTX compares with its peers on the latest reported figures

  • BNTX's LTM Jun 2026 gross margin of 70.8% is the 8th highest of the 11 companies compared; the peer median is 90.3%.
  • Its year-over-year change of -8.9 pp is the 9th highest of 10, against a peer median of +0.1 pp.
  • Over three fiscal years its change of -5.1 pp compares with a peer median of -0.7 pp.
BNTX Competitors Peer median
Gross Margin for BNTX and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
TGTXTG Therapeutics, Inc.LTM Sep 202682.7% -2.6 pp-6.8 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 202653.2% +23.4 pp—
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
Peer median (excluding BNTX) 90.3%+0.1 pp-0.7 pp

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.